24 Aug '23
LumiraDx Reports Second Quarter 2023 Results
LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023. Second quarter 2023 revenues of $21.0 million Submitted First 510(k) Application to the
30 Jun '23
LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
LumiraDx submits a traditional 510(k) Dual Submission for LumiraDx SARS-CoV-2 Ag Ultra with CLIA Waiver for the commercial distribution at point of care of the LumiraDx Platform, including the LumiraDx Instrument, with the LumiraDx SARS-CoV-2 Antigen (Ag) Ultra test, and the LumiraDx SARS-CoV-2 Ag
20 Jun '23
LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
LumiraDx SARS-CoV-2 Ag Ultra & SARS-CoV-2 Ag & RSV tests have been successfully validated by the Medicines and Healthcare products Regulatory Agency (MHRA) under the Coronavirus Test Device Approvals (CTDA) process. These assays join the LumiraDx SARS-CoV-2 Ag and SARS-CoV-2 Ag & Flu A/B assays
16 May '23
LumiraDx Reports First Quarter 2023 Results
LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First quarter 2023 revenues of $22.2 million.
24 Apr '23
LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
LONDON, April 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)(1) for
06 Apr '23
LumiraDx Announces Strategic Refocus and Cost Restructuring Program
LONDON, April 06, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a leading global provider of point-of-care diagnostics testing solutions, today announced its Strategic Refocus and Cost Restructuring Program aimed at reducing its scale and operations to pre-pandemic levels and to further
21 Mar '23
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
LONDON, March 21, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full year ended December 31, 2022. Full year 2022 revenues of $254.5 million.